2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
2
Smoldering Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Interventions
Lenalidomide
17
Dexamethasone
15
Calcium Dobesilate
8
daratumumab
5
dexamethasone acetate
4
dexamethasone 21-phosphate
4
carfilzomib
4
auricularum
4
Melphalan
4
Leflunomide
3
Curcumin
3
isatuximab
2
iberdomide
2
elotuzumab
2
Peripheral Blood Stem Cell Transplantation
2
PVX-410 vaccine
2
Denosumab
2
Cyclophosphamide
2
Bortezomib
2
siltuximab
1
selinexor
1
sargramostim
1
pomalidomide
1
poly ICLC
1
piperine
1
pembrolizumab
1
ixazomib
1
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Smoldering Multiple Myeloma
×
IPH-2101
×
Clear all
NCT01222286
2026-05-14
KIRMONO
Innate Pharma
Phase 2
Completed
30 enrolled
10 charts